$LABT, $0.185. According to PennyGems App stock analysis lakewood-Amedex Biotherapeutics (LABT) rose approximately 256% in the original supplied PennyGems screenshot on November 5, 2026. The company’s financing announcement offers context for that captured move.
LABT: A biotech company removes a source of potential dilution
Lakewood-Amedex, a clinical-stage biotechnology company, announced that it had redeemed all its remaining Series C convertible preferred shares for approximately $1.27 million in cash.
Convertible preferred shares can potentially become common shares, increasing the number of shares outstanding. Redeeming this particular security removes that specific source of potential dilution, though it does not eliminate the possibility of future financing or dilution. The company also used cash to complete the transaction.
The announcement coincided with the largest jump in the screenshot. It is a financing development, not a new drug approval or clinical-trial result. [Company announcement](https://www.streetinsider.com/PRNewswire/Lakewood-Amedex%2BBiotherapeutics%2BAnnounces%2BCompletion%2Bof%2BSeries%2BC%2BConvertible%2BPreferred%2BStock%2BRedemption/27295386.html)
The PennyGems snapshot
The accompanying images show LABT charts and company information captured in PennyGems. Their displayed prices and percentage changes can differ from the original market screenshot because they are separate snapshots. App ratings and news-feed entries are research inputs, not proof of investment value.
Why a redemption can change the financing picture
A convertible preferred security gives its holder contractual rights that differ from those of ordinary shareholders. When conversion is permitted, the holder can receive common shares under the security’s terms. That is why investors pay attention to the number of securities still outstanding, their conversion provisions and the circumstances in which additional common shares could be issued.
The redemption changes that particular financing relationship: cash goes out and the remaining preferred security is retired. It should not be described as money raised for research, operating revenue, or a gain from selling a product. The benefit under discussion is the removal of a potential future claim on the common equity, weighed against the use of cash today.
There are therefore two separate questions for shareholders. The first is whether the transaction simplifies the capital structure. The second is how the company will fund its work after making the payment. A favorable answer to the first does not automatically answer the second. Future financing terms, if any, would need to be evaluated when disclosed.
Keep financing and drug development separate
Lakewood-Amedex’s company website describes its focus on antimicrobial compounds and identifies Nu-3 as its lead compound for infected diabetic foot ulcers. That business background helps explain why clinical progress remains central even when a financing announcement dominates trading attention. [Company background](https://lakewoodamedex.com/)
For an investor following the next announcement, the useful distinction is between changes in the ownership and funding structure and evidence about the underlying research. Trial design, safety observations and clinical outcomes answer different questions from a preferred-stock redemption. Neither a sharp stock-price move nor a simpler capital structure substitutes for those development milestones.
What investors should watch
Redeeming this security removes one potential source of new common shares. Investors still need to assess future funding needs, cash resources and clinical progress. A financing change does not establish whether an investigational medicine will succeed.
News may help explain interest in a stock, but it cannot establish exactly why every trader bought or sold. A large percentage gain does not tell the whole story, and volatile stocks can reverse quickly.
*Price movements are from the supplied PennyGems screenshot and are not live quotes or a recommendation to buy or sell.*
